Wednesday, August 27, 2014

UCB Derived hMSC-MSCGro™ Media-The Wow Factor!

Neuromics-Vitro Biopharma Cells and Media Used to Treat Cerebral Ischemia

I have frequently posted successful outcomes with our Umbilical Cord Blood Derived Human Mesenchymal Stem Cells and MSCGro Expansion Media. These solutions have been tested head to head with other cell and media options and proven superior in cell behavior, doubling time and total number of passages. Competitive testing, until now, was done in culture.

I am pleased to present a study where our cells and media were selected for the the in vivo treatment of Cerebral Ischemia in Rats. This is a key part of building the foundation for human clinical trials: Chelluboina B, Klopfenstein JD, Pinson DM, Wang DZ, Veeravalli KK. Stem cell treatment after cerebral ischemia regulates the gene expression of apoptotic molecules. Neurochemical research. 39(8): 1511-21 DOI: 10.1007/s11064-014-1341-z
Protocol: Cryo-preserved hUCBSCs obtained from Neuromics/Vitro Biopharma (Golden, CO) were used to establish cultures in MSC-GRO low serum complete MSC medium according to the provided instructions. Cultures were maintained at 37 C in a humidified atmosphere containing 5 % CO2 with a change of culture medium twice a week. When the cell cultures were about 80 % to 90 % confluent, cells were split and subcultured. Cells were detached, washed twice with sterile phosphate buffered saline (PBS), counted and suspended in sterile saline prior to intravenous administration. The cells were intravenously injected (0.25 × 10(6) cells or 1 × 10(6) cells) via the tail vein.

Fig: Stem cell treatment after MCAO procedure reduces caspase-dependent apoptosis and brain damage. a Green fluorescence indicates cleaved caspase 3 protein expression. Representative cleaved caspase3 images were merged with respective DAPI images. Scale bar 100 lm. b Quantification of cleaved caspase-3 protein expression in the ipsilateral hemisphere of untreated [15] and hUCBSCs-treated animals. n C 3. Values are expressed as mean ± SEM; *p\0.05 compared to untreated MCAO subjected animals. c Representative hematoxylin and eosin stained paraffinembedded tissue sections from rat brains. Higher magnification images from the ischemic cortex and striatal regions of MCAOsubjected and untreated animals show interstitial edema and damaged neurons that have a condensed, irregular shaped and darkly stained nuclei which are absent or less frequent in control/hUCBSCs-treated brain sections. Each group consisted of a minimum of three animals. Scale bar value for the magnified images = 100 lm

This provides an in-depth understanding of the molecular mechanisms underlying the neuroprotective effects of mesenchymal stem cells derived from human umbilical cord blood in a rat model of transient focal cerebral ischemia. The study clearly demonstrates the potential of hUCBSCs to regulate various molecules responsible for cell death after transient focal cerebral ischemia followed by reperfusion.

There are some other important factors to consider:

  • Potency and Number of Stem Cells Matter-To move this into clinical applications, Doctors must be allowed to expand Mesenchymal Stem Cells.
  • Media used Matters-it must be best in class and not initiate immune inflammatory response.

We will continue to post studies utilizing Neuromics' Stem Cell Solutions.

Friday, August 22, 2014

We Seek Customer Feedback

Customer Service Matters-A Lot!

We use for customer feedback and input. Yes, it is re-assuring to get the rating and feedback featured in this Video.

We are also interested in hearing when all is not well. If there are issues, we will fix them. We offer all our customers free replacements or full refunds. Testimonials like these matter to us:

"Thank you for working with us in the past year to work out some of our antibody issues (we had run into a bad vial of 2AR ab.) Our work will appear next week online in PNAS- we cite the Neuromics antibodies. Have a great new year!" Dr. Laura Bohn, Associate Professor, OSU

You can contact me directly at any time (direct phone: 612-801-1007) or
I stand ready to serve you. Pete Shuster, CEO and Owner, Neuromics

Monday, August 18, 2014

Stem-Kine and Stem Cell Activation

For Health and Fitness

I have referenced our studies of commercially available Stem Cell Activators or Boosters. Many commercially available supplements make claims of boosting the body's ability increase the production of stem cells.

The catalyst for our researching the active ingredients in these boosters was the desire to find a cost effective way to treat clients with certain autoimmune diseases versus the expensive stem cell transplant options.  We also believed that these supplements could also improve athletic performance.

We have an active internal program to test these in culture using our human stem cell based assays and in actual clients. Stem-Kine is one of the supplements we tested proving it to have therapeutic value. Based on our research and testing, we also believe it is capable of increasing athletic performance by boosting the level of Red Blood Stem Cells.

One way we prove therapeutic value is by testing inflammatory/immune response cytokine, growth factors and oxidative stressors in our client’s blood serum using Quantibody Arrays. We test before prescribing Stem-Kine and other activators. We then re-test every 6 months. As an example,  the graph shows results for TNF-alpha and IL-6 (inflammatory response cytokines)  at initial testing levels (red) and re-tests (green). Here we see clear evidence of these 2 cytokines moderating to healthy levels (lower levels for these are better).

To learn more or order by phone, please call me directly at 612-801-1007 or you can also inquire via my direct e-mail: Pete Shuster, CEO and Owner, CA3 Biosciences, Inc. DBA Neuromics

Thursday, August 07, 2014

Pain Research Pubs

2014 Is Already a Record Year

I am pleased with the acceleration of publications by Pain Researchers using our Pain Research Markers and Gene Expression Analysis Tools.

Here's a sampling of the most recent: Transfection Regent Publications: Lili Hou, Yanfeng Zhang, Yong Yang, Kai Xiang, Qindong Tan, Qulian Guo. Intrathecal siRNA Against GPNMB Attenuates Nociception in a Rat Model of Neuropathic Pain. Journal of Molecular Neuroscience. July 2014...Ten micrograms of siRNA1- GPNMB dissolved in 30 μl i-Fect transfection reagent (Neuromics, Edina, MN, USA) was administered intrathecally once daily for 7 days, starting from 1 day before CCI surgery...

TRPV1 PublicationsCapsaicin-responsive corneal afferents do not contain TRPV1 at their central terminals in trigeminal nucleus caudalis in ratsOriginal Research ArticleJournal of Chemical Neuroanatomy, Volumes 61–62, November 2014, Pages 1-12 Deborah M. Hegarty, Sam M. Hermes, Tally M. Largent-Milnes, Sue A. Aicher

New insights into mechanisms of opioid inhibitory effects on capsaicin-induced TRPV1 activity during painful diabetic neuropathy. Neuropharmacology, Volume 85, October 2014, Pages 142-150 Mohammed Shaqura, Baled.I. Khalefa, Mehdi Shakibaei, Christian Zöllner, Mahmoud Al-Khrasani, Susanna Fürst, Michael Schäfer, Shaaban A. Mousa
TRPV1 IF in Mouse DRGs

Mohammed Shaqura, Baled.I. Khalefa, Mehdi Shakibaei, Christian Zöllner, Mahmoud Al-Khrasani, Desipramine and citalopram attenuate pretest swim-induced increases in prodynorphin immunoreactivity in the dorsal bed nucleus of the stria terminalis and the lateral division of the central nucleus of the amygdala in the forced swimming test. DOI: After rinsing with PBS, sections were incubated in PBS containing 0.3% Triton X-100 and 5% normal goat serum at room temperature for 30 min and then incubated with polyclonal guineapig anti-prodynorphin antibody (1:1000, Neuromics, Edina, MN, USA) or polyclonal rabbit ...

All Neuromics' Publications

I will continue to post Pain Research Updates!